AdaptHealth Q2 2026: A 17.6% Guidance Cut, and a GAAP Loss the Adjusted Number Didn't Show

AdaptHealth's headline adjusted number, $0.08 a share, is not the number that describes what happened this quarter. The real one is a GAAP loss of $0.99 a share, against analysts who had modeled a $0.15 gain — a swing of more than a dollar a share between the number the company led with and the number that reflects what actually happened. Shares fell 38.04% anyway, on a report where even the flattering number wasn't good.

What actually happened

Revenue was $740.3 million against an $847.2 million estimate, a 12.6% miss. Adjusted EBITDA was $132 million, an 17.8% margin — itself unremarkable, and dwarfed by what came next: the company cut full-year revenue guidance to a $2.87 billion midpoint from a prior $3.49 billion, a 17.6% reduction, and cut full-year EBITDA guidance to a $505 million midpoint against a $697.2 million analyst estimate.

Why the adjusted number couldn't carry the story

Adjusted EBITDA and adjusted EPS are built to strip out one-time and non-cash items so investors can see the underlying run-rate of the business. That framing works when the underlying business is fine and the adjustments are genuinely one-time. It stops working when the size of the miss and the guidance cut are themselves the story — no adjustment changes a $3.49 billion outlook into a $2.87 billion one. A 17.6% guidance cut is a statement about what management now believes the business will do all year, not a one-quarter accounting item, and no amount of adjusted-metric framing changes that fact.

What to watch

Whether the next quarter's results land inside this newly cut range — a second miss against an already-reduced guide would be a materially worse signal than this quarter's miss against the old one, since it would mean management still doesn't have visibility into its own business.